Veröffentlichungen

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

S. Reinke
P.J. Bröckelmann
I. Iaccarino
M. Garcia-Marquez
S. Borchmann
F. Jochims
M. Kotrova
K. Pal
M. Brüggemann
E. Hartmann
S. Sasse
C. Kobe
S. Mathas
M. Soekler
U. Keller
M. Bormann
A. Zimmermann
J. Richter
M. Fuchs
B. von Tresckow
P. Borchmann
H. Schlößer
M. von Bergwelt-Baildon
A. Rosenwald
A. Engert
W. Klapper

Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial

P.J. Bröckelmann
H. Goergen
U. Keller
J. Meissner
R. Ordemann
T.V. Halbsguth
S. Sasse
M. Sökler
A. Kerkhoff
S. Mathas
A. Hüttmann
M. Bormann
A. Zimmermann
J. Mettler
M. Fuchs
B. von Tresckow
C. Baues
A. Rosenwald
W. Klapper
C. Kobe
P. Borchmann
A. Engert

Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma

B. Edginton-White
P. Cauchy
S.A. Assi
S. Hartmann
A.G. Riggs
S. Mathas
P.N. Cockerill
C. Bonifer

PRISMA: Protein Interaction Screen on Peptide Matrix reveals interaction footprints and modifications- dependent interactome of intrinsically disordered C/EBPb

G. Dittmar
D. Perez Hernandez
E. Kowenz-Leutz
M. Kirchner
G. Kahlert
R. Wesolowski
K. Baum
M. Knoblich
M. Hofstätter
A. Muller
J. Wolf
U. Reimer
A. Leutz

Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma

L. von Hoff
E. Kärgel
V. Franke
E. McShane
K.W. Schulz-Beiss
G. Patone
N. Schleussner
M. Kolesnichenko
N. Hübner
O. Daumke
M. Selbach
A. Akalin
S. Mathas
C. Scheidereit

01. September 2018 in Leukemia

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma

N. Schleussner
O. Merkel
M. Costanza
H.C. Liang
F. Hummel
C. Romagnani
P. Durek
I. Anagnostopoulos
M. Hummel
K. Jöhrens
A. Niedobitek
P.R. Griffin
R. Piva
H.L. Sczakiel
W. Woessmann
C. Damm-Welk
C. Hinze
D. Stoiber
B. Gillissen
S.D. Turner
E. Kaergel
L. von Hoff
M. Grau
G. Lenz
B. Dörken
C. Scheidereit
L. Kenner
M. Janz
S. Mathas

Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group

D.A. Eichenauer
A. Plütschow
S. Kreissl
M. Sökler
J.C. Hellmuth
J. Meissner
S. Mathas
M.S. Topp
K. Behringer
W. Klapper
G. Kuhnert
M. Dietlein
C. Kobe
M. Fuchs
V. Diehl
A. Engert
P. Borchmann

Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma

K.D. Wurster
F. Hummel
J. Richter
M. Giefing
S. Hartmann
M.L. Hansmann
S. Kreher
K. Köchert
D. Krappmann
W. Klapper
M. Hummel
S.S. Wenzel
G. Lenz
M. Janz
B. Dörken
R. Siebert
S. Mathas

Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin's lymphoma

J. Du
M. Neuenschwander
Y. Yu
J.H.M. Däbritz
N.R. Neuendorff
K. Schleich
A. Bittner
M. Milanovic
G. Beuster
S. Radetzki
E. Specker
M. Reimann
F. Rosenbauer
S. Mathas
P. Lohneis
M. Hummel
B. Dörken
J.P. von Kries
S. Lee
C.A. Schmitt